09-16-2012, 11:13 PM
(This post was last modified: 09-16-2012, 11:29 PM by Administrator.)
The Belviq and Qsymia approvals reflect a shift by FDA away from viewing obesity treatments as cosmetics and more as drugs for a growing health problem. Some 75 million Americans (about one-quarter of the U.S. population) are obese, according to American Heart Association.
- Arena Pharmaceutical (ARNA) when it managed to get its obesity drug, Belviq, approved by the FDA on June 27
- Vivus has targeted the fourth quarter to launch Qsymia (phentermine and topiramate extended-release),
- Orexigen Therapeutics's weight loss drug Contrave was rejected by FDA in 2011 assessing cardiovascular (CV) risks.
Source: http://www.genengnews.com/keywordsandtoo...t/3/28581/
- Arena Pharmaceutical (ARNA) when it managed to get its obesity drug, Belviq, approved by the FDA on June 27
- Vivus has targeted the fourth quarter to launch Qsymia (phentermine and topiramate extended-release),
- Orexigen Therapeutics's weight loss drug Contrave was rejected by FDA in 2011 assessing cardiovascular (CV) risks.
Source: http://www.genengnews.com/keywordsandtoo...t/3/28581/
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)